Venus 20

**Venus 20** is an incompletely characterized EMS investigational vaginal-treatment identifier that appears publicly only as the shared \"Venus 20\" component of three single-dose vaginal-cream regimens: Venus 20 + 0.064, Venus 20 + 1, and Venus 20 + 4. These formulations were studied in a randomized, double-blind Phase II trial for vulvovaginal candidiasis, with butoconazole nitrate vaginal cream as the active comparator. Public trial records do not disclose the active ingredient(s), the identity of the dose-varying component, or a molecular target; therefore, a specific mechanism and standalone chemical identity cannot be assigned. The registered trial was withdrawn. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05031481))